Kriya Therapeutics, Inc.

Walk into the conversation about Kriya Therapeutics in 2026 and you find a clinical-stage biotech doing the unfashionable thing: running five gene therapy programs at once, while operating its own manufacturing engine, while insisting the whole point is to treat diseases millions of people actually have. Most gene therapy companies pick a lane. Kriya bought the highway.

Who they are now

A biotech that builds its own factory

Gene therapy has a reputation problem. It works - spectacularly, sometimes - but it has mostly worked for rare conditions affecting a few thousand patients, at prices that read like phone numbers. Kriya looked at that and asked an awkward question: if the science is real, why is the audience so small? Their answer points at the unglamorous middle of the value chain. The bottleneck isn't the gene. It's making enough of the medicine, cleanly and affordably.

So Kriya built a company around manufacturing as much as molecules. The pipeline spans three therapeutic areas - ophthalmology, metabolic disease, and neurology - but the connective tissue is a vertically integrated engine for product design, R&D, and GMP production. It's a biotech that talks about purity, scale, and cost-per-dose the way other biotechs talk about mechanisms of action.

The problem they saw

Rare is a business model, not a destiny

Here is the tension that runs through everything Kriya does. A one-time gene therapy that ends a lifetime of injections is, on paper, the best deal in medicine. In practice, the field drifted toward ultra-rare diseases - partly because the regulatory path is cleaner, and partly because, frankly, you can charge a fortune and only need to make a little. Efficient for the few. A dead end for the many.

Kriya's premise is that this was a manufacturing accident dressed up as strategy. Chronic, prevalent diseases - the ones that fill clinics, not orphan registries - have been treated as off-limits for gene therapy because nobody could produce doses at that volume and cost. Change the factory, and you change the set of diseases worth pursuing.

Money in, one round at a time

DISCLOSED FINANCING BY ROUND // FIGURES APPROXIMATE, USD

Series A '20$80.5M

Series B '21~$100M

Series C '22~$270M

Add-on '24~$150M

Series D '25$320M

The founders' bet

Operators who'd built companies before

Kriya was founded in 2019 by Shankar Ramaswamy and Roger Jeffs, with gene therapy scientist Fraser Wright as scientific co-founder. Ramaswamy, an MD with an economics degree from Harvard, came up through Roivant Sciences and served as Chief Business Officer at Axovant Gene Therapies - a background that explains the company's unusual comfort with treating manufacturing and capital strategy as first-class scientific problems. (He's also, for the trivia-minded, the brother of Roivant founder Vivek Ramaswamy.)

Wright brings the lab credibility, with roots in some of the foundational work that brought gene therapy from promise to approval. Jeffs adds commercial-scale operating experience. The bet they made together: that gene therapy's next decade belongs to whoever can manufacture it at scale, not just whoever discovers the next vector.

The product

Five shots on goal, one engine

Kriya's pipeline reads like a deliberate argument against gene therapy's narrow reputation. Each program targets a chronic condition that affects far more than a handful of patients, and each draws on the same in-house manufacturing and engineering base.

The common design goal: a single administration that produces a durable effect. Inject the instructions once, let the body keep making the therapeutic protein, and a daily-management disease becomes, in theory, a treated one. The qualifier matters - these are clinical and preclinical programs, not approved products. Skepticism is the correct posture. But the shape of the bet is unusually legible.

The proof

What the money is buying

Conviction in biotech is measured in term sheets, and Kriya has collected a stack of them. More than $1.1 billion raised since 2019, capped by a $320 million Series D in September 2025 that the company described as oversubscribed and priced at a step-up to the prior round. The investor list mixes dedicated healthcare capital - Patient Square Capital, Premji Invest, the T1D Fund - with technology-world money including Peter Thiel and Narya Capital.

That blend is telling. The healthcare investors are buying the pipeline. The tech investors are buying the platform - the idea that Kriya is, underneath the biology, a scaled production system. Both groups are wagering on the same thing: that the factory thesis survives contact with the clinic.

The mission

Accessible is the whole point

It would be easy to read “Gene Therapy. Redefined.” as a slogan. Read it instead as a spec. Kriya's stated mission - therapies for the many, not the few - only works if the economics work, which is why a biopharma company spends so much of its energy on purity, scale, and cost. The mission and the manufacturing are the same sentence said two ways.

There's a quiet irony here worth noting. The most radical thing a gene therapy company can do right now may not be inventing a new vector - it may be making an existing kind of medicine boring enough, and cheap enough, to give to ordinary patients. Kriya is betting the unglamorous work is where the revolution actually lives.

Why it matters tomorrow

If the factory thesis holds

Picture the conversation about Kriya a few years out. If even one or two of those five programs clears the clinic at a manufacturable cost, the company stops being a promising biotech and becomes a proof point - evidence that gene therapy can graduate from rare-disease specialty to common-disease standard of care. If the programs stumble, it becomes a well-funded lesson in how hard that graduation is.

Either way, the question Kriya forced onto the table doesn't go away. We opened on a company running five programs at once while building its own factory, insisting gene therapy is for the many. That looked like overreach to some and inevitability to others. The difference between those two readings is exactly what Kriya was built to settle - one durable dose at a time.